Coagulation Function Test in Esophageal Carcinoma and Its Clinical Significance_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

PANGYao ^1,2 ,  ZHUZi-jiang ² , YUANJi-bao ² , XIONGHai-ke ² , WANGWen-hao ²

1. Gansu University of Chinese Medicine, Lanzhou 73000, P.R.China;
2. Gansu Provincial Hospital, Department of Thoracic Surgery 2, Lanzhou 73000, P.R.China;

Corresponding?author：

ZHUZi-jiang, Email: zhuzijiang2005@sina.com

Keywords：

Esophageal carcinoma; Blood coagulation; Clinical significance

DOI：

10.7507/1007-4848.20160130

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To show the changes of coagulation function in patients with esophageal carcinoma, and to explore the clinical significance of the changes. Methods We retrospectively analyzed the clinical data of 202 patients(as a trial group, 114 males, 88 females, aged from 36 to 69 years, median age at 49 years) with esophageal carcinoma confirmed by pathological examination in Gansu Provincial Hospital from January 2010 through May 2014. The prothrombin time (PT), prothrombin time activity (PTA), international activated partial thromboplastin time (APTT), fibrinogen (Fib), D-Dimer, and platelet count, pathological type, TNM stage, gender were recorded. Eighty patients (38 males, 42 females, with aged of 39 to 71 years, median age of 51 years) without cancer were selected as a control group. Results Compared with the control group, coagulation parameters including PT, APTT, PLT, Fib, TT, D-Dimer were statistically higher in the trial group (P<0.05). Higher Fib level was found in the squamous cell esophageal carcinoma patients than adenocarcinoma cell esophageal carcinoma patients (P<0.05). Fib increased significantly (P<0.05) and APTT shorten (P<0.05) in the patients at stage Ⅲ and stage Ⅳ compared with those of patients at stage Ⅰ and stage Ⅱ. Fib and D-Dimer levels increased (P<0.05) in N_1-3 patients compared with those of N₀ patients. There was no statistical difference in gender or age (P>0.05) between the two groups. Conclusion Most of the patients with esophageal carcinoma have abnormal changes of coagulation and fibrinolysis system. Patients with squamous subtype and/or lymph node metastasis at advanced stages of esophageal carcinoma are prone to thrombophilia. So monitoring the coagulation parameters of cancer patients can be used as an effective measure to prevent blood clot.

Citation： PANGYao, ZHUZi-jiang, YUANJi-bao, XIONGHai-ke, WANGWen-hao. Coagulation Function Test in Esophageal Carcinoma and Its Clinical Significance. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2016, 23(6): 542-545. doi: 10.7507/1007-4848.20160130 Copy

1.	Lyman GH, Khorana AA. Cancer,clots and consensus: new understanding of an old problem. J Clin Oncol, 2009, 27(29): 4821-4826.
2.	Struve S, Wendtner CM. Prevention and treatment of venous thromboembolism in patients with cancer. Dtsch Med Wochenschr, 2012, 137(40): 2007-2009.
3.	Kr?ger K, Moerchel C. Deep vein thrombosis: how to care for risk patients. MMW Fortschr Med, 2010, 152(44): 35-39.
4.	Shtherland DE , Wei tz IC, Liebman HA. Thromboembolic compli cations of cancer:epidemiology, pathogenesis, diagnosis,and treatment. Am J Hemato, 2003, 72(1): 43-52.
5.	Sierra-Montenegro E, Sierra-Luzuriaga G, Calle-Loffredo D, et al. Rectal cancer and trousseau syndrome. case report. Cir Cir, 2013, 81(3): 242-245.
6.	Bobek V. Anticoagulant and fibrinolytic drugs - possible agents in treatment of lung cancer. Anticancer Agents Med Chem, 2012, 12(6): 580-588.
7.	Monreal M,Lensing AM,Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. Thromb Haemost, 2004, 2(6): 876.
8.	Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317.
9.	de Oliveira AL, Ribeiro A, Reis LF, et al. Chest radiography as a method of screening for occult cancer in patients with idiopathic deep vein thrombosis. Angiology, 2012, 63(5): 378-379.
10.	Semb VB, Tveit A. Limited malignancy screening of patients with idiopathic venous thromboembolism. Tidsskr Nor Laegeforen, 2014, 134(4): 407-411.
11.	Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood, 2005, 105(4): 1734-1741.
12.	van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood, 2012, 119(4): 924-932.
13.	Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood, 2012, 119(23): 5543-5552.
14.	Anand M, Brat DJ. Oncogenic regulation of tissue factor and thrombosis in cancer. Thromb Res, 2012, 129(Suppl 1): S46-S49.
15.	喻曉潔, 胡小青, 羅兵. 化療對卵巢癌血漿纖維蛋白原和D-二聚體水平的影響. 實用癌癥雜志, 2009, 24(1): 87.
16.	Tiedje V, Dunkler D, Ay C, et al. The role of fibrinogen plasma levels, the-455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost, 2011, 8: 106.
17.	Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost, 2010, 8(1): 114-120.
18.	Mackman N, Tilley RE, Key NS, et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol, 2007, 27: 1687.
19.	Wolberg AS, Mast AE. Tissue factor and factor VIIa--hemostasis and beyond. Thromb Res, 2012, 129(Suppl 2): S1-4.
20.	Owens AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep, 2012, 14(5): 394-401.

1. Lyman GH, Khorana AA. Cancer,clots and consensus: new understanding of an old problem. J Clin Oncol, 2009, 27(29): 4821-4826.
2. Struve S, Wendtner CM. Prevention and treatment of venous thromboembolism in patients with cancer. Dtsch Med Wochenschr, 2012, 137(40): 2007-2009.
3. Kr?ger K, Moerchel C. Deep vein thrombosis: how to care for risk patients. MMW Fortschr Med, 2010, 152(44): 35-39.
4. Shtherland DE , Wei tz IC, Liebman HA. Thromboembolic compli cations of cancer:epidemiology, pathogenesis, diagnosis,and treatment. Am J Hemato, 2003, 72(1): 43-52.
5. Sierra-Montenegro E, Sierra-Luzuriaga G, Calle-Loffredo D, et al. Rectal cancer and trousseau syndrome. case report. Cir Cir, 2013, 81(3): 242-245.
6. Bobek V. Anticoagulant and fibrinolytic drugs - possible agents in treatment of lung cancer. Anticancer Agents Med Chem, 2012, 12(6): 580-588.
7. Monreal M,Lensing AM,Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. Thromb Haemost, 2004, 2(6): 876.
8. Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317.
9. de Oliveira AL, Ribeiro A, Reis LF, et al. Chest radiography as a method of screening for occult cancer in patients with idiopathic deep vein thrombosis. Angiology, 2012, 63(5): 378-379.
10. Semb VB, Tveit A. Limited malignancy screening of patients with idiopathic venous thromboembolism. Tidsskr Nor Laegeforen, 2014, 134(4): 407-411.
11. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood, 2005, 105(4): 1734-1741.
12. van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood, 2012, 119(4): 924-932.
13. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood, 2012, 119(23): 5543-5552.
14. Anand M, Brat DJ. Oncogenic regulation of tissue factor and thrombosis in cancer. Thromb Res, 2012, 129(Suppl 1): S46-S49.
15. 喻曉潔, 胡小青, 羅兵. 化療對卵巢癌血漿纖維蛋白原和D-二聚體水平的影響. 實用癌癥雜志, 2009, 24(1): 87.
16. Tiedje V, Dunkler D, Ay C, et al. The role of fibrinogen plasma levels, the-455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost, 2011, 8: 106.
17. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost, 2010, 8(1): 114-120.
18. Mackman N, Tilley RE, Key NS, et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol, 2007, 27: 1687.
19. Wolberg AS, Mast AE. Tissue factor and factor VIIa--hemostasis and beyond. Thromb Res, 2012, 129(Suppl 2): S1-4.
20. Owens AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep, 2012, 14(5): 394-401.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Coagulation Function Test in Esophageal Carcinoma and Its Clinical Significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content